Mar 15, 20221 min readNEW EVENT THIS THURSDAY! New drug for HER2+ Breast CancerFDA Approved for Adult Patients with HER2+ unresectable or metastatic breast cancer after two or more prior anti-HER2-based regimens in the metastatic setting! Learn more!See program details below! Grab a seat!Invitation - ENHERTU Extending HER2+ Expectations (REF# 6101535 5497606).pdfDownload PDF • 3.04MB
FDA Approved for Adult Patients with HER2+ unresectable or metastatic breast cancer after two or more prior anti-HER2-based regimens in the metastatic setting! Learn more!See program details below! Grab a seat!Invitation - ENHERTU Extending HER2+ Expectations (REF# 6101535 5497606).pdfDownload PDF • 3.04MB
The First and Only Novel Targeted Therapy Approved for mCRC, Regardless of Mutation Status, in More Than a Decade1-3
This event has been rescheduled to April 26th, 2022. New event info coming soon...